These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23585665)

  • 21. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
    Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
    Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
    Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
    Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
    Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
    Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
    Chen X; Hu P; Vaccaro N; Polidori D; Curtin CR; Stieltjes H; Sha S; Weiner S; Devineni D
    Clin Ther; 2015 Jul; 37(7):1483-1492.e1. PubMed ID: 26048186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
    Nyirjesy P; Sobel JD; Fung A; Mayer C; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2014 Jun; 30(6):1109-19. PubMed ID: 24517339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
    Polidori D; Sha S; Mudaliar S; Ciaraldi TP; Ghosh A; Vaccaro N; Farrell K; Rothenberg P; Henry RR
    Diabetes Care; 2013 Aug; 36(8):2154-61. PubMed ID: 23412078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
    Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
    Basile J
    Postgrad Med; 2011 Jul; 123(4):38-45. PubMed ID: 21680987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal effects of canagliflozin in type 2 diabetes mellitus.
    Perkovic V; Jardine M; Vijapurkar U; Meininger G
    Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
    Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
    Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
    Lamos EM; Younk LM; Davis SN
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):763-75. PubMed ID: 23590413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
    Elmore LK; Baggett S; Kyle JA; Skelley JW
    Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
    Yamout H; Perkovic V; Davies M; Woo V; de Zeeuw D; Mayer C; Vijapurkar U; Kline I; Usiskin K; Meininger G; Bakris G
    Am J Nephrol; 2014; 40(1):64-74. PubMed ID: 25059406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
    Matthaei S
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
    Jeong SI; Ban MS; Hwang JG; Park MK; Lim S; Kim S; Kwon SK; Kim Y; Cho JM; Na JJ; Huh W; Chung JY
    Diabetes Obes Metab; 2024 Jul; 26(7):2588-2597. PubMed ID: 38618974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
    Bloomgarden Z
    J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.